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Blood levels of the acute phase reactant C-reactive protein (CRP) are frequently measured 
as a clinical marker for inflammation, but the biological functions of CRP are still contro-
versial. CRP is a phosphocholine (PC)-binding pentraxin, mainly produced in the liver in 
response to elevated levels of interleukin-1β (IL-1β) and of the IL-1β-dependent cytokine 
IL-6. While both cytokines play important roles in host defense, excessive systemic IL-1β 
levels can cause life-threatening diseases such as trauma-associated systemic inflam-
mation. We hypothesized that CRP acts as a negative feedback regulator of monocytic 
IL-1β maturation and secretion. Here, we demonstrate that CRP, in association with 
PC, efficiently reduces ATP-induced inflammasome activation and IL-1β release from 
human peripheral blood mononuclear leukocytes and monocytic U937 cells. Effective 
concentrations are in the range of marginally pathologic CRP levels (IC50 = 4.9 µg/ml). 
CRP elicits metabotropic functions at nicotinic acetylcholine (ACh) receptors (nAChRs) 
containing subunits α7, α9, and α10 and suppresses the function of ATP-sensitive P2X7 
receptors in monocytic cells. Of note, CRP does not induce ion currents at conventional 
nAChRs, suggesting that CRP is a potent nicotinic agonist controlling innate immunity 
without entailing the risk of adverse effects in the nervous system. In a prospective study 
on multiple trauma patients, IL-1β plasma concentrations negatively correlated with 
preceding CRP levels, whereas inflammasome-independent cytokines IL-6, IL-18, and 
TNF-α positively correlated. In conclusion, PC-laden CRP is an unconventional nicotinic 
agonist that potently inhibits ATP-induced inflammasome activation and might protect 
against trauma-associated sterile inflammation.
Keywords: c-reactive protein, interleukin-1β, nlrP3 inflammasome, monocytes, nicotinic acetylcholine 
receptors, sterile inflammation
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inTrODUcTiOn
Interleukin-1β (IL-1β) is a pro-inflammatory cytokine of innate 
immunity that plays a seminal role in host defense (1). Secretion 
of monocytic IL-1β into the circulation in response to severe 
multiple trauma, however, may be more harmful than beneficial, 
as IL-1β is swept away from the site of inflammation, and high 
blood plasma levels can cause systemic inflammatory response 
syndrome (SIRS) and multi organ dysfunction syndrome 
(MODS) (2–5). Despite decades of intensive research, treatment 
of SIRS and MODS is mainly supportive, and mortality remains 
unacceptably high (5, 6).
IL-1β secretion normally requires two consecutive danger sig-
nals (5, 7–9). Ligands of toll-like receptors are typical first signals 
inducing pro-IL-1β synthesis, and extracellular ATP is a typical 
second signal that activates the ATP-sensitive P2X7 receptor 
(P2X7R), induces NLRP3 (NACHT, LRR, and PYD domains-
containing protein 3) inflammasome assembly, caspase-1 activa-
tion, pro-IL-1β cleavage, and secretion of mature IL-1β (7–11). 
The secretion of IL-18 and high mobility group box 1 protein 
(HMGB1) also depends on inflammasome activation (7–13). 
Apart from the ATP-induced pathway typical for trauma-associated 
sterile inflammation, several alternative mechanisms of IL-1β 
maturation are activated during infection (1).
C-reactive protein (CRP) is a pentraxin (14, 15), mainly 
produced in the liver in response to elevated systemic levels of 
IL-1β and IL-6 (14, 15). Blood concentrations of this acute phase 
protein are a frequently used sensitive clinical marker for inflam-
mation. In addition, slightly raised CRP levels correlate with 
cardiovascular disease and some disorders of the central nervous 
system (16–18). The biological functions of CRP are, however, 
highly disputed. CRP seems to play a vital role in humans, 
as its gene was conserved during evolution and there are no 
reports on CRP-deficient individuals (14). It has been proposed 
to be involved in the clearance of pathogens or apoptotic cells 
(14, 15), to induce pro-inflammatory cytokines (19, 20), and to 
play a pathogenic role in cardiovascular diseases (21). At least 
some of the pro-inflammatory effects are mediated by activated 
CRP that exposes binding sites for complement and immuno-
globulins and is mainly found within inflamed tissues (22, 23). In 
contrast to the more pro-inflammatory functions, CRP induces 
high levels of the anti-inflammatory IL-1 receptor antagonist (24), 
and transgenic animals overexpressing human CRP are protected 
from inflammatory diseases including sepsis (25), alveolitis (26), 
arthritis (27), and atherosclerosis (28).
In the presence of Ca2+, CRP associates with phosphocholine 
(PC) and a range of more complex molecules containing a PC 
group at a 1:1 M ratio per CRP monomer (14, 15, 29). Our group 
recently demonstrated that phosphatidylcholines and their 
metabolites including free PC are efficient inhibitors of ATP-
induced release of IL-1β from human monocytes by a mechanism 
that involves non-canonical metabotropic functions of nicotinic 
acetylcholine (ACh) receptors (nAChRs) (30–33).
Here, we demonstrate that purified human endogenous CRP 
(eCRP) efficiently inhibits the ATP-induced release of IL-1β from 
monocytic cells. We provide evidence that CRP presents PC to 
nAChRs and thus potentiates the effect of free PC. PC-laden CRP 
is hence a novel agonist of unconventional nAChRs that controls 
inflammasome activation by inhibiting the function of P2X7R.
MaTerials anD MeThODs
U937 cells
U937 cells (DSMZ, Braunschweig, Germany) were maintained in 
RPMI 1640 (Gibco by Life Technologies, Darmstadt, Germany) 
supplemented with 10% fetal calf serum (FCS, Biochrome, 
Berlin, Germany) and 2  mM l-glutamine (Gibco by Life 
Technologies) under 5% CO2 atmosphere at 37°C. Cells 
(1 × 106 cells/ml) were seeded in 24-well plates, primed for 5 h 
with 1  µg/ml lipopolysaccharide (LPS) from Escherichia coli 
(L2654, Sigma-Aldrich, Deisenhofen, Germany) (30). BzATP 
[2′(3′)-O-(4-benzoylbenzoyl)adenosine 5′-triphosphate triethyl-
ammonium salt; 100 µM, Sigma-Aldrich] or nigericin (50 µM, 
Sigma-Aldrich) were added for another 30 min in the presence or 
absence of different concentrations of eCRP from human pleural 
fluid (Millipore, AG732), recombinant CRP (rCRP) produced 
in E. coli (Millipore, 236608), serum amyloid P (SAP; Millipore, 
565190), or PC chloride calcium salt tetrahydrate (Sigma-
Aldrich). Nicotinic antagonists mecamylamine hydrochloride 
(Sigma-Aldrich), strychnine hydrochloride (Sigma-Aldrich), 
α-bungarotoxin (Tocris Bioscience, Bristol, UK), ArIB [V11L, 
V16D] (500 nM) (34, 35) and RgIA4 (200 nM) (31, 36) were also 
applied together with BzATP. Supernatants were stored at 20°C 
until cytokine and lactate dehydrogenase (LDH) measurement.
human Peripheral Blood Mononuclear 
cells (PBMc)
Peripheral blood mononuclear cells were obtained from healthy 
(self-reported) male non-smoking adult volunteers. The local 
ethics committee at the University of Giessen approved all studies 
on primary human cells (approval No. 81/13). Blood was drawn 
into sterile syringes containing 17.5 IU heparin (Ratiopharm, Ulm, 
Germany) per ml blood and PBMC were separated on Leucosep 
gradients (Greiner Bio-One, Frickenhausen, Germany). LPS (5 ng/
ml) was added to blood samples before gradient centrifugation 
(30). PBMC were cultured in 24-well plates at a density of 5 × 105 
cells/0.5 ml in RPMI 1640, 10% FCS, 2 mM l-glutamine for 3 h. 
Non-adherent cells were removed, and cell culture medium was 
replaced by medium devoid of FCS. Stimulation with BzATP in the 
presence or absence of eCRP was done as described for U937 cells.
cell Viability
Non-Radioactive Cytotoxicity Assay (Promega, Madison, WI, 
USA) was used to measure LDH concentrations in cell free 
supernatants as indicated by the supplier. LDH values are given 
as percentage of the total LDH content of lysed control cells. Cell 
viability was unimpaired in all experimental settings.
cytokine Measurement
Blood concentrations of IL-1β, IL-18, and tumor necrosis 
factor-α (TNF-α) were measured by the Human Quantikine® 
Immunoassays (R&D Systems, Minneapolis, MN, USA). IL-6 was 
measured on the Siemens 150.
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Immulite 2000 XPI system using the Siemens IL-6 reagent 
(Siemens, Erlangen, Germany). HMGB1 was measured by an 
ELISA obtained from IBL International (Hamburg, Germany). 
To detect low cytokine levels in cell culture supernatants, for 
IL-1β the Human IL-1 beta/IL-1F2 DuoSet ELISA (R&D 
Systems) was used, whereas IL6 and TNF-α were measured 
by the Human Quantikine® Immunoassays (R&D Systems, 
Minneapolis, MN, USA).
Dissociation and Formation of crP/Pc 
complexes
Endogenous CRP was dissolved at a concentration of 5 µg/ml in 
PBS devoid of Ca2+ and Mg2+ (Gibco) containing 1.1 mM ethyl-
enediaminetetraacetic acid (EDTA; Sigma-Aldrich), incubated at 
37°C for 15 min followed by ultrafiltration using Amicon® Ultra 
centrifugal filters. The high molecular weight fraction was diluted 
in PBS/EDTA, ultrafiltrated, and transferred to PBS, 5 mM Ca2+, 
without EDTA by two additional ultrafiltration steps. In control, 
the same procedure was performed in the absence of EDTA. 
CRP purified by ultrafiltration and rCRP were incubated at a 1:1 
and 1:3 M ratio per monomer, respectively, with PC at 37°C for 
30 min and tested in IL-1β release assays at a concentration of 
5 µg/ml CRP and 1 µM PC.
gene silencing
The expression of nAChR subunits α7 (CHRNA7), α9 (CHRNA9), 
and α10 (CHRNA10) in U937 cells was silenced by transfection 
of small interfering RNA (siRNA; 30  pmol per 1 ×  106 cells, 
ON-TARGETplus human CHRNA7, CHRNA9, or CHRNA10 
siRNA SMARTpool, Thermo Fisher Scientific, Schwerte, 
Germany) using the Amaxa® Cell line Nucleofector® Kit C (Lonza 
Cologne AG, Cologne, Germany) and the Nucleofector® device 
II (Lonza Cologne AG). Negative control ON-TARGETplus non-
targeting pool (Thermo Fisher Scientific) was included to control 
for non-specific effects of transfection. A reduction of the mRNA 
expression of subunits α9 and α10 to about 50% of control-
transfected cells was recently shown by our group in the same 
experimental setting via real-time RT-PCR 6 h after transfection 
(30). The basal expression of α7 mRNA, however, was too low to 
be quantified. IL-1β release experiments were performed 2 days 
after transfection.
immunocytochemistry
Lipopolysaccharide-primed PBMC were cultured in 
CELLview™ slides (Greiner Bio-One) at a density of 2 × 105 
cells per well in 200  µl medium and stimulated with BzATP 
(100  µM) in the presence or absence of eCRP (5  µg/ml). 
Cells were fixed and permeabilized with ice-cold Cytofix/
Cytoperm™ (BD Biosciences, Heidelberg, Germany) for 
20 min, washed with Perm/Wash™ buffer (BD Biosciences), 
and air-dried before storage at 4°C. Slides were rehydrated 
with Perm/Wash™ buffer, endogenous peroxidase activity 
was inhibited by treatment with 1% H2O2 in Perm/Wash™ 
buffer, followed by 1% bovine serum albumin in Perm/
Wash™ buffer for 30 min at ambient temperature. Polyclonal 
rabbit antibodies to human ASC (1:50, SC-22514-R, Santa 
Cruz Biotechnology, Dallas, TX, USA) or monoclonal mouse 
antibodies to human CD14 (1:100, HCD14, BioLegend via 
Biozol, Eching, Germany) were diluted in Perm/Wash™ 
buffer containing 1% bovine serum albumin and 5% human 
heat-inactivated serum. Bound antibodies were detected 
with horseradish peroxidase-conjugated goat anti-rabbit Ig 
(1:50) and rabbit anti-mouse Ig (1:70) antibodies (both from 
Dako Cytomation, Glostrup, Denmark) and 0.5  mg/ml 3,3′- 
diaminobenzidine (Sigma-Aldrich), 1% H2O2, 0.3  M Tris-
buffered saline, pH 7.6, for 10 min at room temperature. Slides 
were slightly counterstained with hemalumn and cover-
slipped in Glycergel mounting medium (Dako Cytomation). 
Slides were evaluated blinded for the experimental groups at 
a 200-fold magnification using an Olympus BX51 microscope 
and the analySIS software (Olympus, Hamburg, Germany). At 
least 150 cells in 12 fields of vision were counted per experi-
ment. Total numbers of cells and specks were converted into 
mean numbers of specks per 100 cells. In negative controls that 
resulted in no staining, primary antibodies were omitted. The 
specificity of the antibodies to ASC was verified by Western 
blotting of protein extracts from U937 cells that revealed a 
single band with the expected molecular mass (not shown).
gel electrophoresis and Western Blotting
SDS polyacrylamide gel electrophoresis was performed under 
reducing conditions according to Laemmli (37). PBMC were 
lysed, the protein concentration of the lysate was determined 
(Micro BCA protein assay kit, Pierce Biotechnology, Rockford, 
IL, USA) and adjusted to 15 μg/10 μl. Cell culture supernatants 
were harvested at the end of the experiments, concentrated by a 
factor of 10 using Amicon® Ultra centrifugal filters (Ultracel™ 
10K, Merck Millipore, Darmstadt, Germany) and mixed with 
2× sample buffer. Samples (10  µl each) were loaded onto 
15% SDS-polyacrylamide gels, transferred to polyvinylidene 
difluoride membranes (Millipore, Billerica, MA, USA) and 
stained with Brilliant Blue G (Sigma-Aldrich). Prestained 
molecular weight standards (Precision Plus Protein Standards, 
dual color, Bio Rad, Hercules, CA, USA) were separated in each 
gel. Mouse monoclonal antibodies to IL-1β that detect both 
pro-IL-1β and mature IL-1β (1:10,000, 3ZD, kindly supplied by 
the National Cancer Institute, Frederick, MD, USA), polyclonal 
rabbit anti-caspase-1 antibodies (1:1,000, #2225, Cell Signaling 
Technology, Danvers, MA, USA) and mouse monoclonal 
antibodies to β-actin (1:500,000, A2228, Sigma-Aldrich) were 
applied and detected with horseradish peroxidase-conjugated 
rabbit anti-mouse Ig (1:5,000) and goat anti-rabbit Ig (1:5,000) 
antibodies (both from Dako Cytomation). SuperSignal 
West Dura Extended Duration Substrate (Thermo Scientific, 
Rockford, IL, USA) was used to detect IL-1β and Lumi-Light 
substrate (Roche, Mannheim, Germany) to detect β-actin. 
Documentation and densitometry of the blots were performed 
using a digital gel documentation system (Biozym, Hessisch 
Oldendorf, Germany).
Whole-cell Patch-clamp recordings
U937 cells were incubated in poly-l-lysine-coated culture 
dishes (Nunc, Roskilde, Denmark) in bath solution [5.4  mM 
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KCl, 120 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES 
(4-(2-hydroxyethyl)-piperazine-1-ethanesulfonic acid), 25 mM 
glucose, pH 7.4] for 5 h with LPS (1 µg/ml) at 37°C. Thereafter, 
whole-cell recordings were performed at ambient tempera-
ture on an inverted microscope (Axiovert, Zeiss, Göttingen, 
Germany). Patch pipettes were pulled from borosilicate glass 
capillaries (outer diameter 1.6  mm, Hilgenberg, Malsfeld, 
Germany) to a resistance of 2–4 MΩ using an automated puller 
(Zeitz, Augsburg, Germany). Pipettes were filled with pipette 
solution (120  mM KCl, 1  mM CaCl2, 2  mM MgCl2, 10  mM 
HEPES, 11 mM ethylene glycol tetraacetic acid, 20 mM glucose, 
pH 7.3). The membrane potential of LPS-primed U937 cells 
was voltage-clamped to −60 mV and transmembrane currents 
in response to BzATP (100  µM) were amplified with an EPC 
9 amplifier (HEKA, Lambrecht, Germany) and acquired via an 
ITC-16 interface with the Pulse software (HEKA). A pressure-
driven microperfusion system was used to apply BzATP, eCRP 
(5 µg/ml) and RgIA4 (200 nM).
Measurements of intracellular ca2+
To measure intracellular [Ca2+]i, U937 cells were incubated in 
poly-l-lysine-coated glass bottom culture dishes (CELLview™, 
Greiner Bio-One) for 5 h with LPS (1 µg/ml) at 37°C in the 
same bath solution as described for the whole-cell patch-clamp 
recordings. Thereafter, cells were loaded with 3.3 µM Fura-2/
AM (Thermo Fisher Scientific) for 25 min at 37°C. Fura-2/AM 
was excited at 340 and 380 nm wavelengths and the fluorescence 
emission 510 nm was measured. Four independent batches of 
U937 cells were used in this experiment and a total number 
of 243 cells were tracked individually, and the fluorescence 
intensity ratio of 340:380 nm was recorded. Experiments were 
run at room temperature. After a calibration time of 100  s, 
cells were exposed to eCRP (5 µg/ml) for 300 s. At the end of 
the experiments, a positive control for the Ca2+ imaging setup 
was included. Forskolin (40 µM; Biozol), an activator of ade-
nylyl cyclase that elevates cyclic adenosine monophosphate 
(cAMP) levels, was applied to induce a cAMP-triggered rise in 
[Ca2+]i (38).
Two-electrode Voltage-clamp (TeVc) 
Measurements on Xenopus laevis Oocytes 
expressing human nachr
Defolliculated Xenopus laevis oocytes were obtained from Ecocyte 
Bioscience (Castrop-Rauxel, Germany). Oocytes from at least two 
different Xenopus laevis individuals were used in all experimental 
groups. Oocytes were stored in Ringer’s solution (ORi) containing 
(in mM) 90 NaCl, 1 KCl, 2 CaCl2, 5 HEPES, 2.5 pyruvate, 20 mg/
ml penicillin, and 25 mg/ml streptomycin (pH 7.4) at 16°C. All 
chemicals used for ORi preparation were purchased from Fluka 
(Deisenhofen, Germany), except for HEPES, penicillin, and 
streptomycin (Sigma-Aldrich). Plasmid DNAs encoding the 
human CHRNA9 and CHRNA10 as well as the 43 kDa receptor-
associated protein of the synapse (RAPSN) were obtained from 
Eurofins Genomics (Ebersberg, Germany) and capped cRNA was 
synthesized as described before (31). Human CHRNA7 encoding 
cRNA was kindly provided by G. Schmalzing (Department of 
Molecular Pharmacology, RWTH Aachen University, Aachen, 
Germany) and synthesized as described before (33). cRNA was 
dissolved in nuclease-free water and injected into oocytes in a 
volume of 50.6 nl using a microinjector (Nanoject, Drummond 
Scientific, Broomall, PA, USA). Oocytes were injected with 
cRNA encoding CHRNA7, CHRNA9, and CHRNA10 nAChR 
subunits (16, 19, and 19 ng/oocyte, respectively) along with 5 ng 
cRNA encoding RAPSN, and oocytes were incubated at 16°C for 
3–5 days. In control experiments, 50.6 nl of nuclease-free water 
was injected.
In TEVC measurements, oocytes were perfused (gravity driven) 
with ORi without pyruvate and antibiotics (pH 7.4). Intracellular 
borosilicate microelectrodes were filled with 1  M KCl solution 
and the membrane voltage was clamped to –60 mV using a TEVC 
amplifier (Warner Instruments, Hamden, CT, USA). Low-pass 
filtered transmembrane currents (1,000 Hz, Frequency Devices 
902, Haverhill, MA, USA) were recorded using a strip chart 
recorder (Kipp & Zonen, Delft, The Netherlands). For experi-
ments examining the inhibition and recovery from inhibition of 
choline-gated currents in presence and absence of eCRP (5 µg/
ml), oocytes were injected with a 1:1 ratio of cRNA encoding 
human CHRNA9 and CHRNA10 in a 1:1 ratio, incubated at 17°C 
for 2–3 days and measured as described before (31).
clinical study
A single center prospective observational study (trial registration: 
DRKS00010991) was approved by the ethics committee of the 
medical faculty Giessen, Germany (No. 164/14) and performed 
in accordance with the Helsinki Declaration. Written informed 
consent was given by each patient or patient’s legal representative. 
Patients were recruited at the surgical intensive care unit (ICU) 
of the University Hospital of Giessen, Germany from January 
2015 until February 2016. Only patients with severe trauma 
as defined by an injury severity score (ISS) above 16 (39) were 
included. Patients younger than 18  years or with a history of 
HIV or hepatitis B/C infection were excluded. Detailed patient 
characteristics are listed in Table 1.
The first venous blood sample (day 0) was drawn within 15 h 
after admission to the hospital followed by daily blood collec-
tion in the morning. The levels of IL-1β, IL-18, TNF-α, IL-6, 
and HMGB1 were determined in the plasma of heparinized 
blood. CRP levels were analyzed turbidometrically by Siemens 
ADVIA XPT system (Siemens) using the wrCRP reagent 
(Siemens).
Quantification and statistical analysis
SPPS® (Version 23, IBM®, Armonk, NC, USA) and GraphPad 
Prism® (Version 6, GaphPad Software, La Jolla, CA, USA) were 
used for statistical and linear regression analyses. The IC50 value 
of eCRP in human U937 cells was determined in GraphPad 
Prism® (Version 6, GaphPad Software) by fitting log-transformed 
concentration values and the original effect data. Multiple groups 
were first analyzed by non-parametric Kruskal–Wallis test. In 
case of p ≤ 0.05, non-parametric Mann–Whitney rank sum test 
was performed to compare between individual groups and again, 
a p ≤ 0.05 was considered as statistically significant. Paired data 
were analyzed by Wilcoxon sign rank test.
TaBle 1 | Patient characteristics.
number of patients n = 38
Gender male 28 (73.7%)
Age (years) 47.7 ± 20.9
Body mass index (kg/m2) 25.3 ± 3.3
clinical history
COPD 0
Myocardial infarction 1 (2.6%)
Congestive heart failure 0
Renal failure 0
Immunosuppression 0
ISS 25 ± 6
NISS 27 ± 6
Type of injury
Head 24 (63.2%)
Thorax 34 (89.5%)
Abdomen 24 (63.2%)
Extremities 28 (73.7%)
External injuries 35 (92.1%)
cause of injury
Car accident 16 (42.1%)
Motorcycle accident 10 (26.3%)
Bicycle accident 3 (7.9%)
Fall 7 (18.4%)
Other reasons 2 (5.3%)
RISC 2.6 ± 1.3
APACHE II 16.8 (7.5%)
SOFA 7.2 (4.3%)
24 h mortality 1 (2.6%)
30 days mortality 2 (5.3%)
Length of ICU stay (days) 11.2 ± 11.8
Length of hospital stay (days) 23.5 ± 15.2
APACHE II, acute physiology and chronic health evaluation score; COPD, chronic 
obstructive pulmonary disease; ICU, intensive care unit; ISS, injury severity score; 
NISS, new injury severity score; RISC, revised injury severity classification score; SOFA, 
sequential organ failure assessment score.
Data are shown as mean ± SD, as absolute numbers or as percentage.
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resUlTs
crP inhibits aTP-Mediated il-1β release 
From human Monocytic U937 cells
To test if CRP inhibits ATP-induced IL-1β release, we primed human 
monocytic U937 cells for 5 h with LPS (1 µg/ml). Thereafter, 100 µM 
BzATP, a P2X7R agonist (40), was applied for 30 min in presence 
and absence of eCRP and IL-1β concentrations were measured in 
cell culture supernatants. We found that in LPS-primed U937 cells 
the BzATP-induced release of IL-1β was dose-dependently and effi-
ciently inhibited by eCRP (Figure 1A). The half maximal inhibitory 
concentration (IC50) was 4.9 µg/ml corresponding to an about 40 nM 
concentration of pentameric CRP. Of note, plasma levels between 
3 and 10 µg/ml are clinically regarded as a minor pathological CRP 
elevation (41). In contrast to eCRP, the acute phase protein 
(5 µg/ml), another pentraxin with high structural similarity to CRP 
(15), did not inhibit ATP-induced IL-1β release (Figure 1B).
crP Potentiates the inhibitory effect  
of Pc
C-reactive protein, but not SAP, Ca2+-dependently associates with 
PC in a 1:1 M ratio per subunit (15, 29). We previously showed 
that PC efficiently inhibits BzATP-induced IL-1β secretion from 
human monocytes (30, 31). Thus, we hypothesized that the 
inhibitory effect of eCRP on the release of IL-1β depends on its 
association with molecules containing a PC group. Accordingly, 
human rCRP (5 µg/ml) produced in E. coli that is expected to 
be devoid of PC, did not inhibit the BzATP-triggered release 
of IL-1β from LPS-primed U937 cells (Figure  1C), whereas a 
mixture of 5 µg/ml rCRP, 1 µM PC, and 5 mM Ca2+ was fully 
effective (Figure  1C). The same concentration of free PC was 
ineffective (Figure 1C), as expected (30). In a similar approach, 
eCRP was treated with EDTA (1.1 mM) to detach ligands from 
the PC-binding sites and was separated from small molecules by 
ultrafiltration (Figures 1D,E). This resulted in an inactive CRP 
preparation, the activity of which was restored by adding PC 
(1 µM) in the presence of Ca2+ (Figure 1D). Hence, the inhibition 
of ATP-induced IL-1β release by eCRP depends on its association 
with PC. Moreover, as the IC50 eCRP is around 40 nM and that 
of free PC around 10 µM (30, 31), CRP potentiates the inhibitory 
effect of PC by at least two orders of magnitude.
ecrP signals via nachrs
Next, we tested if eCRP signals via nAChRs in human monocytic 
U937 cells. Indeed, the eCRP-dependent inhibition of ATP-
induced IL-1β release was completely reversed by the non-selective 
nAChR antagonist mecamylamine (100 µM). Similar results were 
obtained by using α-bungarotoxin (1 µM) or strychnine (10 µM), 
both preferential antagonists of the α7 and α9 nAChRs (42–44). 
The α-conotoxins ArIB [V11L, V16D] (500  nM) (34, 35) and 
RgIA4 (200 nM) (31, 36) that are specific for nAChRs composed of 
subunits α7 and α9α10, respectively, also completely blocked the 
inhibitory effect of eCRP (Figure 1F). These results indicate that 
eCRP signals via nAChRs containing subunits α7, α9, and α10. To 
corroborate the involvement of these nAChR subunits, U937 cells 
were transfected with siRNA targeting CHRNA7, CHRNA9, and 
CHRNA10. Indeed, single-gene silencing of each nAChR subunit 
significantly blunted the inhibitory effect of eCRP (Figure 1G).
ecrP Does not Trigger ion channel 
Functions at conventional nachrs
The canonical ionotropic function of nAChR can be monitored by 
using Xenopus laevis oocytes as heterologous expression systems 
(45). To investigate if eCRP elicits ionfluxes human nAChR subu-
nits α7, α9, and α10 were heterologously expressed in oocytes to 
perform TEVC measurements. We showed that eCRP (5 µg/ml) 
did not induce ion currents, whereas the classical nAChR agonist 
choline did (Figures 2A–C). Nevertheless, eCRP interacted with 
canonical nAChRs, as it reduced choline-triggered currents in 
oocytes expressing α9α10 nAChRs (Figures 2D,E). Thus, eCRP 
does not trigger canonical ion channel functions of nAChRs but 
acts as a silent agonist or partial antagonist that modulates the 
responses to classical nicotinic agonists.
ecrP inhibits BzaTP-induced current 
responses in Monocytic cells
Next, we tested if eCRP induces ion fluxes in LPS-primed 
U937 cells. Application of eCRP (5  µg/ml) did not induce ion 
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FigUre 1 | Continued
FigUre 2 | Purified human endogenous C-reactive protein (eCRP) does not induce ion channel functions at canonical nAChRs. Two-electrode voltage-clamp 
(TEVC) measurements were performed on Xenopus laevis oocytes that heterologously expressed human nAChR subunits α7, α9, and α10. (a,c) The application of 
the known nAChR agonist choline (Cho1, 2 min, 1 mM, black bars) induced a stimulation of the transmembrane ion current (IM) that could be repeated by a second 
Cho application (Cho2; n = 7). (B,c) By contrast, eCRP (5 µg/ml) did not provoke current responses, whereas a subsequent Cho application did (n = 6). (c) All 
changes of IM (ΔIM) induced by cholinergic stimulation are shown as individual data points, bars represent median, whiskers encompass the 25th to 75th percentile. 
Wilcoxon signed-rank test. (D) Representative current traces of Cho-gated currents in oocytes expressing α9α10 nAChRs illustrating the inhibitory effect of eCRP 
(5 µg/ml). The current traces represent 30 s recordings each and are shown concatenated omitting the 30 s gap between each individual trace. The oocytes were 
continuously perfused with saline solution and stimulated with Cho (1 s pulses, 1 mM) once per min until steady-state baseline responses were observed (indicated 
by the arrow). Subsequently, the Cho-gated currents were monitored in the presence of eCRP for changes in amplitude for 12 min. Thereafter, eCRP was washed 
out and the Cho-gated currents were monitored for recovery. (e) Graphical representation and analysis of the experimental results shown in (D). Mean and SEM 
from five oocytes.
FigUre 1 | Purified human endogenous C-reactive protein (eCRP) inhibits BzATP-induced release of interleukin-1β (IL-1β) from U937 cells. 
Lipopolysaccharide (LPS)-primed (1 µg/ml, 5 h) U937 cells were stimulated with BzATP (2′(3′)-O-(4-benzoylbenzoyl)adenosine 5′-triphosphate 
triethylammonium salt; 100 µM) and IL-1β was measured 30 min later in cell culture supernatants. (a) eCRP dose-dependently inhibited the BzATP- 
induced IL-1β release, nicotine (Nic; 100 µM) served as a positive control. (B,c) Serum amyloid P (5 µg/ml), human recombinant CRP (rCRP) (5 µg/ml), or low 
concentrations of free phosphocholine (PC) (1 µM) did not impair IL-1β release, but a combination of rCRP and PC (1 µM) did. (D) The inhibitory effect of 
eCRP (CRP I; 5 µg/ml) was preserved after ultrafiltration (cutoff 10 kDa; CRP II), but abolished by ultrafiltration in the presence of ethylenediaminetetraacetic 
acid (1.1 mM; CRP III). PC (1 µM) reconstituted the activity of CRP III, whereas 1 µM PC alone was ineffective. (e) CRP was retained in CRP III and absent 
from the low molecular weight fraction (LMW). SDS-PAGE followed by staining with Brilliant Blue. (F) The effect of eCRP was reversed by nicotinic 
acetylcholine receptor (nAChR) antagonists mecamylamine (Mec; 100 µM), α-bungarotoxin (α-Bun; 1 µM), strychnine (Stry; 10 µM), ArIB (500 nM), and RgIA4 
(200 nM). (g) In experiments using small interfering RNA (siRNA), silencing of the nAChR subunits α7, α9, and α10, but not control siRNA (con) attenuated the 
inhibition by eCRP. Data are presented as individual data points, bar represents median, whiskers encompass the 25th to 75th percentile. *p ≤ 0.05, different 
from LPS-primed cells stimulated with BzATP alone. #p ≤ 0.05, different LPS-primed cells were stimulated with BzATP and eCRP. Kruskal–Wallis followed by 
Mann–Whitney rank sum test.
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FigUre 3 | Purified human endogenous C-reactive protein (eCRP) suppresses BzATP-induced whole-cell currents via nAChRs. (a) BzATP-induced ion currents 
were detected by whole-cell patch-clamp measurements in lipopolysaccharide (LPS)-primed (1 µg/ml, 5 h) U937 cells. Repetitive current changes were provoked by 
two (1, 2) consecutive BzATP (100 µM) applications (upper panel). Application of eCRP (5 µg/ml) alone did not provoke ion currents but fully inhibited the response 
to BzATP (middle panel). The inhibitory effect of eCRP was antagonized by addition of the α9α10 nAChR-specific α-conotoxin RgIA4 (200 nM; lower panel).  
(B) Graphical presentation of the two consecutive BzATP-induced ion current changes (1, 2, ΔIBzATP). (c) [Ca2+]i of LPS-primed U937 cells were recorded as Fura-2/
AM (Fura-2) fluorescence intensity ratio of 340:380 nm excitation (mean ± SEM). Application of eCRP (5 µg/ml; indicated by arrow) did not cause significant 
alterations in [Ca2+]i (values before eCRP compared to values obtained 300 s after eCRP application: p = 0.726). At the end of the experiments, a positive control for 
cell viability and the Ca2+ imaging setup was included: forskolin (Fsk, 40 µM, indicated by arrow) was applied to induce a cyclic adenosine monophosphate-triggered 
rise in [Ca2+]i. (D) The ATP-independent release of interleukin-1β (IL-1β) from LPS-primed monocytic U937 cells induced by nigericin (Nig; 50 µM) is neither inhibited 
by nicotine (Nic; 100 µM) nor by various concentrations of eCRP. Data are presented as individual data points, bar represents median, whiskers encompass the 25th 
to 75th percentile (B,D). Wilcoxon signed-rank test (B,c) or Kruskal–Wallis followed by Mann–Whitney rank sum test (D).
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currents in whole-cell patch-clamp experiments (Figures 3A,B) 
and intracellular Ca2+ levels remained unchanged (Figure 3C). 
By contrast, BzATP (100 µM) induced a robust and repeatable 
current response in LPS-primed U937 cells (Figures 3A,B), as 
reported previously (30, 31). Remarkably, in the presence of eCRP, 
the BzATP-induced current responses were completely abrogated 
(Figures 3A,B). The inhibitory effect of eCRP was sensitive to the 
α-conotoxin RgIA4 (Figures 3A,B), confirming the involvement 
of nAChR subunits α9 and/or α10.
NLRP3 inflammasomes, in addition to extracellular ATP, 
assemble in response to other pro-inflammatory stimuli 
including pore-forming toxins (1). Here, the pore-forming 
bacterial toxin nigericin was used to investigate if eCRP also 
affects ATP-independent IL-1β release, which was clearly not 
the case (Figure 3D). Hence, stimulation of nAChRs with eCRP 
efficiently inhibits BzATP-induced ion currents in monocytic 
U937 cells but does not provoke canonical ion channel func-
tions of nAChRs.
FigUre 4 | Purified human endogenous C-reactive protein (eCRP) inhibits BzATP-induced release of interleukin-1β (IL-1β) from human peripheral blood 
mononuclear cells (PBMC). PBMC freshly isolated from healthy volunteers were pulsed with lipopolysaccharide (5 ng/ml) during the process of PBMC isolation and 
cultured for 3 h. The cells were stimulated with 100 µM BzATP in the presence or absence of eCRP (5 µg/ml) for 30 min. (a) IL-1β, (B) IL-6, and (c) TNF-α were 
measured by ELISA in cell culture supernatants (n = 5). Data points obtained from individual blood donors are coded by different colors and connected by lines. 
Wilcoxon signed-rank test.
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ecrP inhibits inflammasome activation in 
human PBMc
We performed experiments on the adherent fraction of freshly 
isolated PBMC from healthy human donors that were primed 
with a short pulse of LPS (5 ng/ml) during cell isolation. The 
spontaneous secretion of IL-1β by these cells was low, whereas 
a considerable amount of IL-1β was released in response 
to BzATP (100  µM). Indeed, eCRP (5  µg/ml) significantly 
attenuated the BzATP-induced release of IL-1β from these 
cells (Figure  4A), whereas the inflammasome-independent 
cytokines IL-6 and TNF-α (46) were neither induced by BzATP 
nor regulated by eCRP (Figures 4B,C). The concentrations of 
IL-6 and TNF-α released within 30 min after BzATP application 
are low and all apparent changes in response to BzATP or eCRP 
are not significant and probably random. We reported before, 
that almost no IL-18 is secreted by these cells in response to 
BzATP (30).
Inflammasome activation can lead to the formation of 
large aggregates, so-called specks or pyroptosomes, that can 
be detected with antibodies directed to ASC (apoptosis-
associated speck-like protein containing a caspase activation 
and recruitment domain) (1). To investigate if CRP inhibits 
inflammasome and caspase-1 activation in primary monocytic 
cells LPS-pulsed PBMC were challenged with BzATP (100 µM) 
in the presence and absence of eCRP (5 µg/ml). A significant 
increase in ASC speck formation was detected in LPS-primed 
PBMC in response to BzATP, which was largely suppressed 
by concomitant application of eCRP (Figure  5A). Pro-IL-1β 
and pro-caspase-1, but not their mature forms, were detected 
by Western blotting of cell lysates of LPS-primed PBMC 
stimulated with BzATP in the absence or presence of eCRP 
(Figure  5B). In concentrated supernatants, however, mature 
caspase-1 and IL-1β were detectable upon BzATP-treatment, 
and eCRP significantly reduced their amount (Figures 5C,D). 
We conclude that CRP suppresses inflammasome assembly, 
pyroptosome formation, activation of capase-1 and maturation 
of IL-1β.
crP and il-1β levels negatively correlate 
in Multiple Trauma Patients
Our in  vitro experiments led to the provocative hypothesis that 
elevated CRP levels protect against trauma-induced release of 
IL-1β into the circulation in vivo. We performed a prospective 
study on multiple trauma patients admitted to our hospital. 
Patient characteristics are summarized in Table 1. Plasma lev-
els of IL-1β, IL-18, IL-6, TNF-α, and HMGB1 were measured 
in blood drawn at daily intervals until day 4 after admission. 
During the first 2 days, IL-1β levels negatively correlated with 
CRP values of the preceding day (Figures 6A–D), which is in 
line with our hypothesis. On day 4 after trauma, plasma levels 
of IL-6 (Figure S1 in Supplementary Material), IL-18 (Figure 
S2 in Supplementary Material), and TNF-α (Figure S3 in 
Supplementary Material) positively correlated with CRP values 
on day 3, whereas no correlation was seen for HMGB1 (Figure 
S4 in Supplementary Material). On days 0–2 after trauma, 
IL-1β levels did not correlate with disease severity acute 
physiology and chronic health evaluation score (APACHE II) 
and sequential organ failure assessment score (SOFA). In 
patients who remained on the ICU on days 3–4 after trauma 
a negative correlation of IL-1β levels with the SOFA score was 
seen (Table S1 in Supplementary Material). This subpopulation 
of patients typically suffers from a severe disease course. CRP 
levels did not correlate with APACHE II and SOFA score (Table 
S2 in Supplementary Material). Albeit statistically significant 
(p ≤ 0.05), the correlation coefficients (r) and, accordingly, the 
coefficients of variation (CV) (Figure  6; Figures S1–S4 and 
Tables S1 and S2 in Supplementary Material), do not prove 
causality.
FigUre 5 | Purified human endogenous C-reactive protein (eCRP) inhibits BzATP-induced inflammasome activation, caspase-1 activation, and maturation of 
interleukin-1β (IL-1β) in human peripheral blood mononuclear cells (PBMC). (a) ASC specks (arrows) were detected by immunocytochemistry using antibodies 
directed to ASC (brown staining). Cell nuclei were lightly counterstained with hemalum. Specks were induced by treatment with BzATP and occurred less frequently 
when eCRP was added concomitantly (n = 7). (B–D) Western blot experiments were performed using antibodies that detect both, the pro-forms and the mature 
forms of caspase-1 and IL-1β, respectively (n = 5). Cell lysates and cell culture supernatants were investigated from lipopolysaccharide (LPS)-primed PBMC (1), 
LPS-primed PBMC stimulated with BzATP (2), and LPS-primed PBMC stimulated with BzATP in the presence of eCRP (3). (B) Pro-caspase-1 and pro-IL-1β were 
detected in cell lysates at about equal amounts irrespective of stimulation with BzATP, whereas no mature forms were present, although the antibodies used detect 
both the pro-forms and the native forms. Detection of β-actin was included as a loading control. (c) Only mature caspase-1 and (D) IL-1β were present in 
concentrated cell culture supernatants. Stimulation with BzATP induced the release of both proteins and the release was reduced by eCRP. Immunoreactivity was 
measured by densitometry [optical density (OD)]. Data points obtained from individual blood donors are coded by different colors and connected by lines. Wilcoxon 
signed-rank test.
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DiscUssiOn
C-reactive protein is among the most frequently used clinical 
marker of inflammation, but its biological function is still a mat-
ter of debate. Here, we demonstrate that eCRP dose-dependently 
and efficiently inhibits the ATP-induced release of IL-1β from 
monocytic U937 cells at an IC50 of 4.9 µg/ml, corresponding to 
a marginally elevated blood CRP level (41). The activity of eCRP 
depends on the Ca2+-dependent interaction with a small mol-
ecule, presumably PC (14, 15), and on nAChR subunits α7, α9, 
and α10. Stimulation of monocytic nAChRs in turn fully inhibits 
ATP-induced ion currents (Figure  7). Furthermore, eCRP is 
also active in primary human adherent PBMC, where it inhibits 
inflammasome and caspase-1 activation. First clinical evidence 
from multiple trauma patients is in line with the results obtained 
in vitro but does not prove causality. As IL-1β and IL-6 are the 
main inducers of hepatic CRP synthesis during systemic inflam-
mation and IL-1β is an important stimulus for IL-6 expression, 
we suggest that CRP is a negative feedback regulator of the ATP-
dependent production of mature IL-1β by human monocytes 
(Figure 7).
CRP is commonly regarded as an opsonizing agent that 
binds to PC present on the surfaces of some pro- and eukaryotic 
pathogens as well as on dying cells (14, 15). Phagocytosis of these 
opsonized particles is mediated via complement fixation and 
binding of CRP to different Fc-receptors expressed by phago-
cytic cells (14, 15). The suggested role of CRP in host defense 
against infections is, however, in sharp contrast to a large body 
FigUre 6 | High levels of C-reactive protein (CRP) negatively correlate with low interleukin-1β (IL-1β) levels in trauma patients. A prospective clinical study was 
performed on patients suffering from multiple traumata. Plasma levels of IL-1β were measured at daily intervals from the day of admission (day 0) until day 4 after 
trauma and a correlation analysis was performed with CRP values obtained one day earlier. (a) IL-1β at day 1 versus CRP at day 0 (n = 36), (B) IL-1β at day 2 
versus CRP at day 1 (n = 31), (c) IL-1β at day 3 versus CRP at day 2 (n = 23), and (D) IL-1β at day 4 versus CRP at day 3 (n = 21). Linear regression analysis, 
r = correlation coefficient, CV = coefficient of variation.
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of literature showing that PC-containing cell surface molecules 
of bacteria as well as PC-modified proteins secreted by helminths 
exert anti-inflammatory functions leading to immune evasion 
and chronic colonization of the host (47, 48). We demonstrated 
before that PC-modified bovine serum albumin and PC-modified 
lipooligosaccharides from Haemophilus influenzae control the 
release of IL-1β via mechanisms resembling those of CRP (30). 
This suggests that pathogens with PC-modified surfaces hijacked 
the here described mechanism, which underscores the biological 
and medical relevance of CRP.
We identify nAChRs composed of subunits α7, α9, and α10 as 
receptors for eCRP. Our data corroborate the almost 30 years old 
finding, that CRP binds Ca2+-dependently to human monocytes 
with an EC50 of about 2.3 mg/l (49). Presumably, these authors 
measured the PC-dependent binding of CRP to monocytic 
nAChRs. We showed that PC-free CRP is inactive, and its activ-
ity can be reconstituted by adding low concentrations of PC that 
are in the range of those present in the serum of healthy persons 
(50). Thus, the interaction of eCRP with the ligand-binding site 
of nAChRs is probably mediated by CRP-bound PC. It has been 
shown before that endogenous human CRP can be laden with 
PC and other molecules with a PC group (14, 15, 29). In the same 
line, we demonstrated recently that high concentrations of free 
PC also inhibit the ATP-mediated release of IL-1β via nAChR 
(30–33), suggesting that CRP potentiates the effect of free PC. 
This is of importance in vivo, since typical human blood plasma 
concentrations of free PC are about 2 µM (50), while the IC50 of 
free PC is in the range of 10 µM, and 100 µM are needed for a full 
inhibition of the ATP-induced release of monocytic IL-1β (30).
Ligand-binding sites of conventional pentameric nAChRs 
that function as ligand-gated ion channels are formed by two 
neighboring nAChR subunits each and close upon binding of 
their cognate agonists (51). Interestingly, binding of a single 
ligand to only one of the five sites is sufficient for maximal 
ionotropic response of α7 nAChRs and additional binding sites 
enhance agonist sensitivity (52). The nAChR binding sites are 
dimensioned for classical nicotinic agonists but are certainly 
too small to enclose a macromolecule such as eCRP, suggesting 
FigUre 7 | Suggested mechanism of the mutual control of C-reactive 
protein (CRP) and interleukin-1β (IL-1β) during trauma-associated sterile 
inflammation. Injury causes the release of cytoplasmic danger-associated 
molecular patterns (DAMP) and ATP, and frequently microbiota, a source of 
pathogen-associated molecular patterns (PAMP), get access to the damaged 
tissue. DAMP and PAMP can bind to pattern recognition receptors such as 
toll-like receptors (TLR) at monocytic cells and induce the synthesis of 
pro-IL-1β, the inactive cytoplasmic precursor of IL-1β. Extracellular ATP 
activates the P2X7R and leads to inflammasome assembly and caspase-1 
activation. Activated caspase-1 cleaves pro-IL-1β and enables the release of 
mature bioactive IL-1β that in turn, induces IL-6. IL-1β and IL-6 activate the 
hepatic synthesis of CRP and blood levels of CRP quickly rise to 1,000-fold. 
We demonstrated that purified human endogenous CRP inhibits the 
response of P2X7R to ATP via nAChR subunits α7, α9, and α10. The function 
of CRP critically depends on its association with small molecules such as 
phosphocholine (red dots) that seem to mediate the interaction with nicotinic 
receptors. We suggest that the CRP-mediated control of ATP-induced IL-1β 
release is a negative feedback loop that controls excessive systemic 
inflammation in response to injury. Although the nAChR is illustrated as a 
pentamer, its molecular structure remains to be elucidated.
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that the structures of monocytic nAChRs are different. The 
activation of nAChR by a large molecule like eCRP is surpris-
ing but not unprecedented, as we demonstrated before that 
PC covalently bound to bovine serum albumin, PC-modified 
lipooligosaccharides and dipalmitoyl phosphatidylcholine func-
tion as potent agonists at unconventional monocytic nAChRs 
(30, 32). The IC50 values of PC-modified bovine serum albumin 
and lipooligosaccharides are also in the nanomolar range and 
hence, considerably lower than free PC, choline, or acetylcholine 
(30). If the structure of monocytic nAChRs differs from classi-
cal pentamers, it might be speculated that one eCRP pentamer 
interacts with several monocytic nAChRs. Once CRP binds to a 
nAChR, other receptors might be quickly recruited and activated. 
This hypothesis might explain the observed low IC50 values and 
the steep dose-response curve. This hypothesis may also apply to 
PC-modified albumin and to PC-lipooligosaccharides, because 
the PC-albumin investigated contained nine PC groups per 
BSA (30) and lipooligosaccharides tend to form micelles due to 
their amphiphilic structure. In contrast to the above-mentioned 
molecules with covalent PC modifications, it is also possible that 
eCRP delivers free PC to nAChRs because the affinities of PC to 
both molecules are in the same range (53). However, the consid-
erably lower IC50 value of CRP compared to free PC (30) speaks 
against his theory. It may, however, explain, why eCRP acts as a 
silent agonist at canonical nAChRs heterologously expressed by 
Xenopus oocytes. Nevertheless, the structure of such unconven-
tional nAChRs that exert metabotropic functions remains to be 
elucidated and it is even unclear if the leukocytic nAChR subunits 
form pentameric receptors at all.
Increasing evidence suggests that leukocytes in general respond to 
nicotinic stimuli via nAChRs with metabotropic responses, and 
no ligand-gated ion channel functions have been reported so far 
(44, 45, 54). A prominent example is the cholinergic regulation of 
the transcription and translation of pro-inflammatory cytokines 
by macrophages that is mediated via nAChR subunit α7 (54, 55). 
Here, we demonstrate that the P2X7R function of monocytic cells 
and the ATP-dependent release of IL-1β are fully inhibited by 
eCRP via stimulation of nAChRs containing subunits α7, α9, and 
α10. Nicotine, choline, and free PC exert similar effects albeit at 
much higher molar concentrations (30, 31, 33). The molecular 
signaling mechanism down-stream of monocytic nAChRs is 
currently under investigation.
Of note, eCRP neither induces ionotropic functions at 
monocytic nAChRs containing subunits α7, α9, and α10, nor 
at conventional nAChRs that were heterologously expressed 
by Xenopus oocytes. Similar results were shown before for free 
PC (31). Seemingly, eCRP is a novel agonist of nAChRs that 
exclusively induces metabotropic receptor functions and does 
not activate canonical ionotropic nAChR functions of excitable 
cells. Furthermore, we show that eCRP down-modulates the 
choline-induced ionotropic activity of heterologously expressed 
α9α10 nAChRs and provide evidence that CRP might be a silent 
agonist of nAChRs. As CRP and the nAChR subunits α7, α9, 
and α10 were highly conserved during evolution (14, 15, 51, 56), 
and mononuclear phagocytes are already present in primitive 
multicellular organisms (57), we speculate that the control of the 
P2X7R by nAChRs might be, in an evolutionary sense, older than 
neurotransmission.
We showed for the first time that in patients suffering from 
multiple traumata, IL-1β blood levels negatively correlated with 
preceding CRP levels. These results are in line with the hypothesis 
that the CRP-mediated control of IL-1β release is active in vivo, 
albeit they do not prove causality. According to Hill’s criteria for 
causation (58), “a small association does not mean that there is 
not a causal effect, though the larger the association, the more 
likely that it is causal.” Hill lists further criteria for causation 
including temporality, biological gradients, plausibility, and 
experimental evidence. Although, our data by and large meet 
with these criteria, more experimental and larger clinical multi-
center studies are warranted, before we can dare to claim causal-
ity. The absence of a negative correlation of CRP levels with IL-18 
and HMGB1 may be due to the ubiquitous expression of these 
inflammasome-dependent mediators, in contrast to IL-1β which 
is mainly produced by monocytes/macrophages (59).
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Our data suggest that elevated CRP levels attenuate inflam-
matory diseases that are caused by ATP-induced inflammasome 
activation. It remains to be investigated if the here described 
mechanism also contributes to the protection against experi-
mental inflammation in animals overexpressing human CRP 
(25–28). Interestingly, CRP was recently shown to impair den-
dritic cell development, maturation and function (60). This anti- 
inflammatory mechanism involves the inhibitory Fcγ receptor IIB 
(60). The potential clinical implications of these and our findings 
deserve further investigation, including a careful consideration 
of the known pro-inflammatory functions of CRP (14, 15, 22).
Several therapeutics targeting IL-1 or its receptor, among 
them the IL-1 receptor antagonist anakinra, the decoy receptor 
rilonacept and the neutralizing monoclonal anti-IL-1β antibody 
canakinumab, were tested in large trials but never reached the 
clinical arena for the treatment of SIRS (4). A major disadvantage 
of these approaches might be the general inhibition of IL-1β that 
should result in an impaired host defense against infections. By 
contrast, we showed that eCRP specifically inhibits the P2X7R-
mediated response to extracellular ATP that is a danger signal 
mainly associated with mechanical cell damage (61). Viral, bac-
terial, and fungal pathogens activate numerous additional ATP-
independent pathways of inflammasome activation and IL-1β 
maturation (1). Hence, we speculate that CRP predominantly 
inhibits trauma-associated release of IL-1β without preventing 
the IL-1β response to infection.
In conclusion, CRP efficiently inhibits ATP-dependent inflam-
masome activation and IL-1β release from human monocytic 
blood cells in vitro. This effect of CRP seems to depend on bound 
PC and activation of non-canonical nAChRs that efficiently 
inhibit the ion channel functions of monocytic ATP receptors. In 
the same line, we provide the first clinical evidence that elevated 
CRP levels might reduce systemic IL-1β release in patients suffer-
ing from multiple traumata.
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